So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.

IDH-mutant glioma, caused by abnormalities in a specific gene (IDH), is the most common malignant brain tumor among young ...

CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...

The Bulls N’ Bears ASX Runner of the Week is… Hydrix Ltd, which locked in a $2.5million deal to develop SynCardia’s next-gen ...

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

Researchers have unlocked a way to grow the immune system’s “conductors” from stem cells, bringing ready-made cancer-fighting therapies a big step closer. For the first time, scientists at the Univers ...

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Ascidian Therapeutics and Forge Biologics have partnered to advance the development and manufacturing of ACDN-01.

This article explores the US and EU compliance requirements to ensure patient safety for GMP ancillary materials in cell and ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...